Leading pharmaceutical companies frequently "cut meat" because three major imitations and category 1 new drugs will impact the market

Tianshili 1.5 billion sales of wholesale leader, Beida 250 million transfer technology companytable 1: 2019 Tianshi marketing performance (units: 10,000 yuan)Source: Company Announcement
According to Tianshili major asset sales report (draft) data show that Tianshi Marketing is a controlling subsidiary of listed companies The main business is the distribution and distribution of pharmaceutical, medical devices, health care products and other products of third-party pharmaceutical industry enterprises, and in 2019 Tianshi Marketing's operating income is 13.4 billion yuan, accounting for 70.71 percent of the total revenue of listed companies, with total assets of 9.17 billion yuan, accounting for 38.20 percent of the total assets of listed companiesTianshi Marketing was listed on the new three boards from August 15, 2017 to January 3, 2020, and has been known as the "New Three Boards and One Brother", ranking 20th in the national pharmaceutical wholesale main business revenue in 2019Tian Shili said that through the sale of this asset, focus on the advantages of resources to focus on the pharmaceutical industry, continue to promote the coordinated development of modern Chinese medicine, biological drugs and chemical drugs, and build an innovative pharmaceutical research and development clusterAt the same time, the company through the sale of Tianshi marketing assets will effectively reduce the ratio of assets and liabilities, improve the company's operating cash flow, improve shareholder return on investment, and further improve the quality of operations and operational efficiency" heavy medicine holding subsidiary of the "takeover man" heavy drug shares will be no higher than 9.41 yuan per share, the acquisition of Tianshi Marketing not less than 158 million shares, the total share price does not exceed 1.489 billion yuan, after the completion of the acquisition of Tianshi Marketing will be consolidated statementsIn the future, the main business of heavy pharmaceutical shares will be added 5 blank provinces and municipalities directly under the Central Government coverage, in the national pharmaceutical wholesale enterprise ranking is expected to enter the top sixOn June 15,, Beida Pharmaceuticals announced the sale of the wholly-owned subsidiary's equity and related transactions, to sell to Ningbo Keming Innovation Technology Co., Ltdthe entire stake in Zhejiang Beda Pharmaceutical Technology Co., Ltd., the transaction value of 251 million yuanBeida Pharmaceuticals said that the main project of the target company is the construction of the hatching base of Haichengyuan, has been completed, as a listed company based on innovative drugs, the company's research and development investment in large, long cash cycle, through the sale of the target company's equity, can achieve the rapid return of funds to support the development of innovative drugs business, in order to enhance the company's core competitivenessTianshili research and development investment of more than 800 million, 3 first imitation is worth looking forward to
According to Tianshili annual report data show that in 2019 the company invested 810 million yuan in research and development, accounting for 4.26% of the company's operating income, accounting for 13.03% of the pharmaceutical industry revenueTable 2: From 2019 to today Shili approved productssource: Minnet MED China Drug Review Database 2.0 According to Minet data, since 2019, A total of 6 products have been successfully approved, of which hemp antispasm particles have become the only approved pediatric chinese medicine in the past five years Hemp antispasm particles for the company's exclusive varieties, indications for Tourette syndrome (pumping-filth syndrome) and chronic extraction disorder, with the effect of calming the liver and yang, the air to stop spasms, clear the fire sputum heDara non-4 types of imitation approved and treated as the same, so far has been rated up to 6 enterprises In 2019, TOP20, a drug product for chemical urology systems in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as public medical institutions in China), ranked sixth in the tadalafi a piece with sales of more than 130 million yuan In the second batch of national collection stage, Tianshi LiYi Pharmaceuticals and Changchun Haiyue Pharmaceuticals won the bid, Tianshili won Beijing, Tianjin and other 16 cities, is expected to usher in 2020 will usher in the release in the consistency evaluation, the demomine capsule, right zopicyclon tablets, pyrapaaaamine tablets, hydrochloride benzene seaso tablets have been reviewed, together with hedarafi film, as of now, Tianshili has been reviewed or reviewed as well as 5 products The pyrethroid capsule is a heavy product of Tianshili, in 2019 in China's public medical institutions terminal sales broke 1.3 billion yuan, currently only Tianshili a review; Table 3: 2019 to today Shili in the review of the listing application and consistency evaluation Source: MED China Drug Review Database 2.0 2019 to date, TianshiLi in the review of the listing application involves 5 products, including left Shubili tablets, benzene Zabeit release tablets, hydrochloric acid Mei-King Kong release capsuleist is expected to win the first imitation Left Shubili tablets are currently only Tianshili declared imitation and in the review; Shaanxi step-high-tech pharmaceutical Benzene-Benzene slow release tablet 6 imitation was approved in 2016 after the clinical no latest news, there is no other enterprise acceptance number in the review; in addition, the injection of pyridine is currently only Hengrui in 2019 to obtain production approval, after the listing of sales all the way up, the current Sichuan Huiyu Pharmaceutical, Osaikang Pharmaceuticals, Tianshili 3 types of generic listing applications are in the review and approval, finally who can follow Hengrui after the listing, we wait and see Shubili 2019 sales of about 68 million yuan, the leading enterprise Enhua Pharmaceutical market share of more than 50%, Tianshili ranked second, market share of about 11%, the product is currently no enterprise evaluation, only Tianshili's consistency evaluation supplementary application in the review and approval, won the first review of the day Beida Pharmaceuticalresearch research and development investment accounted for more than 40% of revenue, 1 class of new drug Nsatinib listed in the Beida Pharmaceuticals is a typical innovative pharmaceutical company, the company's main product selling for 2011 independent research and development of 1.1 new drug Etryni, as of the end of 2019, the cumulative sales of the product exceeded 7 billion yuan The company's overall performance growth has slowed after Ektini entered the health-care trade-in, especially after the company's performance has been under pressure In recent years, the company adhered to new drug research and development, through independent research and development and strategic cooperation, gradually enriched the company's research and development pipeline, in 2019 the company's research and development investment reached 675 million yuan, accounting for 43.41 percent of operating income, an increase of 14.33 percent over the same period in 2018 Class 1 new drug hydrochloric acid ensatinib capsules listed on the market, for previous progress after treatment of coctininib or tolerance to the coctinininia-positive interstatle lymphoma kinoma (ALK) positive local late or metastatic non-small cell lung cancer (NSCLC) patients, is currently in the CDE review stage, has submitted replacement data, approved for listing into the countdown Table 4: Beida Pharmaceuticals 2019-present Clinical Lyn1 New Drug Source: MED China Drug Review Database 2.0 BPI-28592 is a new type of powerful, highly selective protomy ball Protein receptor kinase (TRK) (also known as neurotrophic receptor tyrosine kinase (NTRK) second-generation oral small molecular inhibitors, can cover a variety of cancer species, intended to carry NTRK gene variants of local late or metastatic solid tumor patients treatment It is reported that only two TRK inhibitors in the world to commercialize, of which Larotrectinib (Larotinib) is listed in the United States, Entrectinib (Entrectinib) is listed in the United States and Japan, and there are no TRK inhibitors on the Chinese market BPI-27336 tablets are a new type of powerful, selective extracellular regulatory kinase 1/2 (ERK1/2) oral small molecule inhibitors for RAS/RAF/MEK activation variants of colorectal cancer, pancreatic cancer, lung cancer, liver cancer, stomach cancer, melanoma and other solid tumor treatment, no global list of ERK1/2 inhibitors BPI-23314 tablets are a powerful, highly selective bromine domain and end-end extraterritorial (BET) oral small molecular inhibitors, which can regulate the transcription of cancer-related genes by specifically inhibiting the function of BET family protein, and then affect cell growth, proliferation, apoptosis and other physiological processes, and finally reach the growth of tumors, approved single drugs for malignant blood system tumors (acute myeloid almost leukemia, non-hogkin leukemia) On June 15, , Beida Pharmaceuticals announced that the application for listing of Beval-Zhusing single injection (MIL60) was accepted by CDE Minnet data show that the current domestic market has Roche approved imports, Qilu Pharmaceuticals in December 2019 approved production, Shandong Green Leaf Pharmaceuticals, Suzhou Shengdia Biopharmaceuticals (Hengrui subsidiary), Cinda Biopharma's listing application is being reviewed and approved concluded in recent years, the new policy of medical reform has emerged, the pharmaceutical industry has suffered a major reshuffle Tianshili as a traditional Chinese medicine enterprises, but also to biological drugs, chemical drugs and cooperative development of the road transformation, the most burning of the road of innovation, this time 1.5 billion sold Tianshi marketing, it can be seen that it for innovation under the heavy book Beida Pharmaceuticals to innovative drugs to make a name for it, in recent years there are many new drugs approved clinically, to resolve the risk of a single product, only to continue to promote research and development, accelerate product market Recently, Xinbang Pharmaceuticals also want to sell two subsidiaries, the total amount of equity transfer of 750 million, the purpose is also to focus on the main industry, it can be foreseen that similar "cut meat" events will continue to occur, however, for the pharmaceutical industry will be the necessary choice to extract refinement source: Company announcement, Minnet database review data statistics as of June 16, 2020
original title: 250 million, 1.5 billion .. Leading pharmaceutical companies frequently "cut meat" reason exposure! 3 first imitation, class 1 new drug will hit the market